The US FDA’s May 2024 calendar of user fee goal dates is slight in comparison to the coming wave of applications with June goal dates, but what the range of pending applications makes up for what it may lack in volume, the Pink Sheet US FDA Performance Tracker’s User Fee Goal Dates tracker shows.
The agency soon will be deciding on a new vaccine for the massive adult respiratory syncytial disease market, what could be the second gene therapy for an ultra-rare pediatric connective tissue disease, a once-daily prodrug of parathyroid hormone that was recently approved in
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?